106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2021 All rights reserved.
ASCOOLI09213
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO® practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines do
not account for individual variation among patients. is pocket guide does not purport to suggest any
particular course of medical treatment. Use of the practice guidelines and this resource are voluntary.
e practice guidelines and additional information are available at www.asco.org/neurooncolog y-
guidelines. Copyright © 2021 by American Society of Clinical Oncolog y. All rights reserved.
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-based B Benefits
outweigh
harms
H High Strong
CB/
FC
Consensus-
based/Formal
Consensus
H Harms
outweigh
benefits
M Moderate Moderate
IC Informal
consensus
B/H Relative
balance of
benefits
and harms
L Low Weak
N No
recommendation
U Benefits/
harms
ratio
uncertain
N Not
considered
Abbreviations
CNS, central nervous system; IDH, Isocitrate Dehydrogenase; MGMT, O -methylguanine-DNA
methyltransferase; PVC, probarbazine, lomustine, vincristine; RT, radiation therapy; TMZ, temozolomide;
WHO, World Health Organization
Source
Mohile NA et al. erapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO
Guideline J Clin Oncol. 2021
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/neurooncolog y-guidelines.
